
Bajaj Consumer Q4 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 4
Margin
Category 1
Fundraise
N/A
Order
N/A
Capex
Yes
2 of 3 growth signals are positive.
Full analysisRevenue guidance
Category 4- The company anticipates strong growth in coming quarters driven by improved market conditions and capability building efforts.
- Almond Drops Hair Oil (ADHO), the core brand, is expected to recover and see meaningful growth, especially as general trade and distribution improve.
- Banjara’s acquisition is projected to contribute significantly, with expectations to surpass FY25 sales of Rs. 53 crores, primarily impacting Q2, Q3, and Q4 of FY26.
- The international business demonstrates robust growth with a 26% annual increase and strong quarter-on-quarter traction, expected to continue.
- E-commerce and modern trade channels show consistent growth, with efforts to expand reach and distribution through Project Aarohan underway.
- New product developments (NPDs) like Almond Drops Hair and Skin Care range and coconut oil are growing strongly and expected to scale further.
- Overall, the company is confident of moving "one or two notches higher" in performance and achieving higher topline and EBITDA margin improvements going forward.
See what Bajaj Consumer management said on margin guidance — free account, 30 seconds.
Fundraise plans
See what Bajaj Consumer management said on order book — free account, 30 seconds.
Capex plans
YesTrack Bajaj Consumer — get its next earnings analysis in your feed
How does Bajaj Consumer rank vs peers in Personal Products?
Pro featureHow does Bajaj Consumer rank in Personal Products?
Compare Bajaj Consumer against every Personal Products company (Q4 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Bajaj Consumer's management said in earlier quarters
Others in Personal Products this season
- Anondita Medicare Ltd (Q3 FY26)
Revenue from operations (Standalone) for H1 FY26: ₹4,765.06 lakh; H1 FY25: ₹2,497.06 lakh; YoY growth: 91% (Page 26) . Key investor presentation takeaways from
- Anondita Medicare Ltd (Q4 FY26)
Current unexecuted order book stands at approximately INR137 crores, which remains intact from the previous year. Key concall takeaways from Anondita Medicare…
- Cupid Ltd (Q4 FY24)
6,289 Lakhs, up 57.04% QoQ and 51.59% YoY from Rs. Key concall takeaways from Cupid Ltd's Q4 FY24 earnings call — and how it ranks against sector peers.
- Cupid Ltd (Q1 FY25)
Total Income (₹ in Lakhs): . Key concall takeaways from Cupid Ltd's Q1 FY25 earnings call — and how it ranks against sector peers.